GlassScriptPhysician profile
Huan Duy Le
NPI 1902986664
$6,550.07
in general payments reported to CMS, 2019-2025
35 companies · $47.34 in 2025
The $47.34 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,394 · 2020: $1,622 · 2021: $2,318 · 2022: $60.68 · 2023: $61.80 · 2024: $46.15 · 2025: $47.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,337.52 | 2019-2022 | |
| Abbvie INC. | $893.17 | 2019-2023 | |
| Amgen INC. | $644.60 | 2019-2021 | |
| Astellas Pharma US INC | $441.69 | 2019-2024 | Veozah |
| Novo Nordisk INC | $367.68 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $360.85 | 2019-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.49 | 2019-2021 | |
| Lilly USA, LLC | $313.28 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $249.56 | 2020-2022 | |
| Glaxosmithkline, LLC. | $247.48 | 2019-2020 | |
| Pfizer INC. | $190.68 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $177.24 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $129.46 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.35 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $102.36 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $92.75 | 2019-2021 | |
| Allergan, INC. | $73.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.27 | 2019 | |
| Ironwood Pharmaceuticals, INC | $48.86 | 2019-2021 | |
| Esperion Therapeutics, INC. | $41.72 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $40.44 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $34.95 | 2021 | |
| Eyevance Pharmaceuticals LLC | $34.95 | 2021 | |
| Philips North America LLC | $29.16 | 2019 | |
| Sanofi Pasteur INC. | $24.96 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $19.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.16 | 2019 | |
| Therapeuticsmd, INC. | $17.58 | 2019 | |
| Vivus LLC | $17.12 | 2019 | |
| Mylan Specialty L.P. | $15.87 | 2019 | |
| Ibsa Pharma INC. | $15.39 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.01 | 2019 | |
| Optinose US, INC. | $13.94 | 2020 | |
| Electromed, INC. | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huan Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.